Amicus Therapeutics Is A Biotechnology Company Dedicated To Developing High Quality Medicines For Individuals With Rare And Orphan Diseasesfounded In 2002 In Cranburynew Jerseythe Company Has Been Publicly Traded Since 2007 Under The Nasdaq Symbol Foldjohn Crowley Has Served As Chairman And Ceo Since 2005Guiding The Company S Mission To Improve The Lives Of Patients The Company Specializes In Small Molecule Drugsparticularly Pharmacological Chaperoneswhich Are Used To Treat Rare Diseasestheir Product Lineup Includes Galafoldmigalastatfor Fabry Disease And Pombiliti And Opfolda For Pompe Diseaseamicus Also Engages In Enzyme Replacement Therapy For Pompe Diseasefollowing Its Acquisition Of Callidus Biopharma In 2013With Operations In Multiple Countriesamicus Therapeutics Aims To Provide Access To Essential Treatments For Patients Worldwide
